Anirban Ghosh - NBIF - FINB
Français
Close

Anirban
Ghosh

Atlantic Cancer Research Institute

Biochemist

Anirban Ghosh
Anirban Ghosh

Investment
$220,000

Industry
Biosciences

Finding new ways to study cellular anomalies

Anirban Ghosh is working to integrate Atlantic Cancer Research Institute patented capture technology and develop a chip to enrich and study extracellular particles. They can use these particles to detect diseases like cancer faster and less invasively than ever before.

Ghosh, adjunct professor at the Université de Moncton in the chemistry and biochemistry departments and member of the ACRI team, is developing an Enricher-Lab-on-Chip (ELOC) to provide new and better ways to study these particles shed by cells. The information contained in them can be used to tell if there are anomalies. It’s tapping into a biological communication network.

The ACRI team developed the Vn96 peptide that captures microvesicles and exosomes. These particles are found in body fluids like blood, urine, and saliva. We can spare a bit of these fluids, rather than going through procedures like biopsies. The capture technology takes the pain out of the whole process, and it’s much faster.

The Vn96 capture technology goes beyond processes like centrifugation, which uses centrifugal force to separate substances. The Vn96 is a molecule that binds to the anomalies.

Lab-on-chip incorporates microfluidics, a field consisting of disciplines like biochemistry, engineering and nanotechnology, with micromechanics and microelectronics. It’s the future of diagnostic medicine because not only is it fast, but it has a high process rate.

The chemistry is cost effective and the technology is versatile. The plan is to immobilize the Vn96 peptide on the ELOC. This chip can aid in conducting diagnostic tests in clinical settings on site at the care facility close to the patients, and they can even be easily adapted for use in the animal health industry.

The healthcare and food safety industry needs ways to detect biological and chemical compounds, and ACRI’s capture technology has the potential to be immediately applied to diagnostics and address this need.